翰林大学春川圣心医院 (President Lee Jae-jun) announced on the 29th that it recently signed a memorandum of understanding (MOU) with the 翰林大学 Medical Bio Convergence Research Institute, IonCell Co., Ltd. (CEO Kim Hyung-soo), and RudaCure Inc. (CEO Yongho Kim) for 联合研究 on CAR-T and ADC drugs.
This MOU was established to integrate the core technologies and capabilities of each institution in order to develop effective therapeutics and, further, to contribute to the advancement of the medical bio industry at both the regional and national levels.
The specific terms of the agreement include: 1) mutual sharing of expertise and technology between the institutions; 2) joint development of CAR-T and ADC drugs; and 3) provision of innovative treatments and therapies to patients. Through this agreement, the core technologies and infrastructure of each institution—including the excellent 临床数据 held by 翰林大学春川圣心医院, the drug screening technology of IonCell Co., Ltd., and the drug 疗效 evaluation and therapeutic development technology of RudaCure Inc.—are expected to generate synergies. The 联合研究 will aim to develop therapeutics utilizing Chimeric Antigen Receptor T-cell (CAR-T) technology and treatments based on Antibody-Drug Conjugates (ADC), referred to as a next-generation cancer treatment technology.
* Sources
[Edaily] https://www.edaily.co.kr/news/read?newsId=01449766635843440&mediaCodeNo=257
[Uigye Sinmun] https://www.medworld.co.kr/news/articleView.html?idxno=227581